Cingulate (NASDAQ:CING) Receives Buy Rating from HC Wainwright

Cingulate (NASDAQ:CING)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research note issued to investors on Thursday,Benzinga reports. They presently have a $20.00 target price on the stock. HC Wainwright’s target price would suggest a potential upside of 431.91% from the company’s previous close.

A number of other equities research analysts have also weighed in on CING. Roth Mkm initiated coverage on Cingulate in a research report on Friday, January 10th. They issued a “buy” rating and a $12.00 price objective on the stock. Maxim Group upgraded shares of Cingulate from a “hold” rating to a “buy” rating in a report on Wednesday, November 20th. Finally, Roth Capital upgraded shares of Cingulate to a “strong-buy” rating in a report on Friday, January 10th.

Cingulate Trading Down 2.3 %

Cingulate stock opened at $3.76 on Thursday. Cingulate has a 1-year low of $1.80 and a 1-year high of $20.83. The firm has a 50-day moving average of $4.59 and a 200-day moving average of $5.02.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in CING. Geode Capital Management LLC bought a new stake in shares of Cingulate during the fourth quarter valued at approximately $135,000. Commonwealth Equity Services LLC raised its holdings in Cingulate by 281.5% in the fourth quarter. Commonwealth Equity Services LLC now owns 43,022 shares of the company’s stock worth $212,000 after purchasing an additional 31,746 shares in the last quarter. AlphaMark Advisors LLC lifted its position in Cingulate by 50,000.0% during the fourth quarter. AlphaMark Advisors LLC now owns 5,010 shares of the company’s stock valued at $25,000 after buying an additional 5,000 shares during the period. Finally, Jane Street Group LLC bought a new stake in shares of Cingulate during the 3rd quarter valued at $106,000. Hedge funds and other institutional investors own 41.31% of the company’s stock.

Cingulate Company Profile

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.